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ABSTRACT
BRAF protein is a serine/threonine kinase with 766 amino acids. Approximately 15% of human cancers harbor BRAF 
mutations as well as other BRAF anomalies (amplifications, fusions). Somatic mutations mainly occur in the catalytic kinase 
domain (CR3), and the predominant mutation is p.V600E which is the substitution of glutamic acid (E) for valine (V) as result 
of a mutation at codon 600 of the kinase domain. To our knowledge, the vast majority of the cancers have non-germline 
BRAF mutations. Here we describe a case of a 60-year-old female with a history of hairy cell leukemia (HCL) who presented 
with aphasia and forgetfulness. A follow-up Brain CT scan showed three distinct brain lesions which were found to be 
diagnostic of melanoma (confirmed by immunohistochemistry) with no evidence of a concurrent brain involvement by a 
B-cell neoplasm. Molecular studies confirmed the same BRAF p.V600E mutation in both malignancies (hairy cell leukemia 
and melanoma). Thereafter the patient was started on BRAF inhibitor treatment and is now symptom-free after one year 
of follow up. Having two concurrent malignancies with a shared BRAF mutation is extremely rare and makes this an 
excellent example of a genomic marker-driven treatment in two histologically and immunophenotypically distinct tumors. 
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BACKGROUND
BRAF mutation was first described in 1993 and 
soon after was found to be one of the most frequently 
mutated protein kinase genes in human tumors.1 
Currently, BRAF mutation is commonly tested in 
pathology practice and has a prognostic and diagnostic 
value in many tumors including HCL, melanoma, thyroid 
cancer, colorectal cancers, brain tumors and various 
other cancers. It has shown to be an effective target 
for cancer treatment, but a key question is whether 
targeted drugs approved for one type of histology 
could be used for other histologic types harboring the 
same aberration. In 2015, Blachly et al.2 presented the 
first case of the co-occurrence of malignant melanoma 
and HCL, both harboring the BRAF p.V600E mutation 
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and its successful treatment with the BRAF inhibitor 
dabrafenib. Here we also present another rare case 
of concurrent BRAF p.V600E positive melanoma 
and HCL which were successfully treated with 
dabrafenib-trametinib combination targeted therapy 
on both malignancies.
CASE REPORT
A 62-year-old female presented in 1993 with 
marked cytopenias and splenomegaly which were 
subsequently found to be secondary to hairy cell 
leukemia (HCL) and treated with cladribine. Thereafter 
she experienced multiple disease relapses while on 
cladribine and rituximab. Most recently she presented 
in 2015 with a progressively worsening headache 
and expressive aphasia. Follow up brain imaging 
revealed new brain lesions (Figure 1) which were 
shown to be consistent with metastatic melanoma 
(Figure 2A to 2D). The follow-up bone marrow showed 
involvement by the patient’s known hairy cell leukemia 
with no evidence of melanoma.
Histology: The H&E slides of the brain mass 
showed sheets of abnormal tumor cells with round 
nuclei and prominent red nucleoli (Figure 2A) with an 
immunophenotype (PAX5 negative, CD20 negative, 
S100 positive, HMB45 positive, and MelanA positive) 
which is consistent with melanoma (Figure 2B to 2D).
Flow cytometry of the bone marrow demonstrated a 
monotypic B-cell population with an immunophenotype 
(CD19+/CD20++/CD11c+/ dimCD103+ /dimCD25+) 
consistent with Hairy cell leukemia (Figure 3A and 3B).
The bone marrow biopsy showed a hypocellular 
marrow (20-30% of cellularity) with an atypical 
interstitial B-cell infiltrate (Figure 4A and 4B). 
By immunohistochemistry, these B-cells were positive for 
PAX5 and DBA44 (Figure 4C and 4D) as well as Annexin 
A1. CD34 and CD117 immunostains highlighted rare 
scattered immature myeloid precursors. S100 and 
HMB-45 immunostains were negative. Peripheral 
blood smear showed pancytopenia with rare atypical 
lymphocytes with villous projections. Overall, given the 
immunophenotype and morphology, the findings were 
consistent with relapsed hairy cell leukemia.
Figure 1. A – Brain axial computed tomography shows brain masses with significant vasogenic edema; B – Brain 
magnetic resonance image weighted in T2 shows brain mass with a targetoid appearance and a central non-enhancing 
lesion, suggestive of necrosis, surrounded by vasogenic edema.
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Figure 2. Photomicrography of the brain biopsy with all of the above images being at 400x magnification. A – H&E 
sections of the excisional biopsy show sheets of neoplastic epithelioid cells with round nuclei and variably prominent 
red nucleoli; By immunohistochemistry, the tumor cells are negative for CD43 – B; and diffusely positive for S100 – C; 
and Melan-A – D.
Figure 3. A, B – Flow cytometry of the bone marrow shows an abnormal CD19+/CD20++ /CD11c+ /dimCD25+ 
monotypic B-cell population, consistent with relapsed Hairy Cell Leukemia.
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Molecular Study: BRAF p.V600E mutation 
(c.1799T>A) was detected by the Real-Time PCR 
(Quantitative) in both the Hairy Cell Leukemia and 
the melanoma.
Treatment: Further work-up (physical examination 
and PET scan) failed to reveal the primary site of the 
metastatic melanoma brain lesions. Therefore, she 
underwent CNS radiation therapy in July 2015 and 
initiated systemic therapy with Mekinist (trametinib) 
2 mg tablet (a MAP2K1/2 inhibitor) in combination with 
Tafinlar (dabrafenib) 75 mg capsule (a BRAF inhibitor). 
She tolerated treatment well and enjoyed a significant 
response; all of the patient’s brain lesions were 
resolved radiologically, and her neurologic symptoms 
diminished in few months. Complete blood count and 
peripheral blood smear showed no evidence of residual 
HCL. As of June 2017, she remains clinically stable and 
reveals no overt evidence of significant clinical disease 
progression.
To our knowledge case reports do not require IRB 
review at our institution.
DISCUSSION
BRAF  gene is  on chromosome 7q34 and 
has 18 exons. BRAF protein is a serine/threonine 
kinase with 766 amino acids composed of 3 conserved 
Figure 4. Photomicrography of the bone marrow A, B – H&E sections of bone marrow show mildly hypocellular 
(~30% cellularity) bone marrow with decreased trilineage hematopoiesis and increased abnormal interstitial 
lymphocytes; C – IHC staining for PAX5 shows positive staining in the abnormal B-cells; D – DBA-44 immunostain 
highlights the abnormal cells of the HCL.
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regions (CR); CR1 and CR2 are regulatory domains, 
and CR3 contains a catalytic protein kinase domain 
(Residues 457-717).3 BRAF somatic missense mutations 
most commonly occur in CR3 region especially at 
codon 600 which leads to constitutive BRAF protein 
kinase activity. 80-90% of all V600 mutations are due 
to NM_004333.4 (BRAF): c.1799T>A (p.Val600Glu), 
which is the substitution of the wildtype allele, 
amino acid Valine-600 (Val, V) with a Glutamic acid 
(Glu, E).4 dbSNP and COSMIC correspondences for 
this mutation are rs113488022 and COSM18443 
respectively. In addition to mutations, other types 
of BRAF aberrations are found in cancer, including 
amplification and BRAF fusions.5,6 BRAF germline 
mutations have also been reported in association 
with developmental disorders including Noonan 
syndrome (NS) and Cardio-facio-cutaneous syndrome.7 
These germline BRAF mutations are different from 
those found in cancers.
BRAF is under the RAF (Rapidly Accelerated 
Fibrosarcoma) protein kinase family. The proto-oncogenes 
of the RAF family include ARAF, BRAF, and CRAF (currently 
known as RAF1). BRAF (serine/threonine-protein 
kinase BRAF) was first isolated in 1993 from a rodent 
retrovirus, and its malignant potential was discovered 
when inoculated normal mouse fibroblasts transformed 
into neoplastic fibrosarcoma cells.1 In 2002, BRAF was 
first found in human tumors.8 Normally, dividing 
cells display surface receptors that bind to growth 
factors present in the surrounding environment. 
This leads to activation of a family of gene products 
that stimulate cell growth (RET). Activated RET binds 
to RAF by a GTP-dependent mechanism. Subsequent 
phosphorylation of serine and threonine residues by 
RAF present on the proteins of the mitogen-activated 
protein kinase pathway (MAPK/ERK) send signals to the 
nucleus. Mutated RAF leads to constitutive activation 
of the downstream signaling pathways. This allows the 
cell to bypass the G1 restriction point of the cell cycle 
with upregulation of cyclin D1, resulting in unchecked 
cellular proliferation and survival.9 The MAPK pathway 
is frequently dysregulated in cancer, often via mutations 
of its intracellular components or activation of growth 
factor receptor tyrosine kinases. Among the three 
forms of RAF kinases, BRAF is the most potent.10
BRAF gene mutations are reportedly associated 
with papillary thyroid carcinoma (30-70%)9, malignant 
melanoma (50%), HCL, adenocarcinoma of the lung 
and colon (5-20%) and ovarian cancer (15-30%).2 
The discovery of mutations in BRAF heralded a 
new era of targeted therapy. HCL and melanoma 
of particular are noted to have shown a dramatic 
response to BRAF inhibition.11, 12
V e m u r a f e n i b  a n d  d a b r a f e n i b  a r e  t w o 
FDA-approved BRAF inhibitors that proved to be 
effective in the treatment of BRAF p.V600E-mutated 
melanoma patients.13 However, resistance can 
occur, and possible mechanisms are due to the 
decreased negative feedback of the EGFR pathway 
as a result of BRAF p.V600E inhibition especially in 
colorectal cancers (CRCs).14 Unlike CRCs, melanoma 
cells express low levels of EGFR. Therefore, EGFR 
pathway does not play an important role in BRAF 
inhibitor resistant melanomas. Another mechanism 
of resistance could be due to mutations other than 
p.V600E codon or RAF1 activation. Emerging data 
suggest that BRAF inhibitors may sometimes be 
better used in combination therapies rather than 
sole treatment (e.g., a BRAF inhibitor together with 
an EGFR or MAP2K1/2 inhibitor) to impacts relevant 
co-activated pathways.15 Trametinib is currently the 
only FDA approved MAP2K1/2 inhibitor which also 
approved in combination use with dabrafenib for 
melanoma. According to the current studies on the 
HCL treatment, vemurafenib is on phase II clinical 
trial, and dabrafenib showed effective responses in 
the case reports.16
CONCLUSION
The discovery of BRAF mutations in a wide range of 
cancers shows a great deal of promise in personalized 
medicine and is a major driver for the rapid drug 
development of such targeted therapies across a 
variety of malignancies. However, the approach may 
ultimately lead to genomic marker-driven treatments 
independent of their histology and immunophenotype. 
Our case report was a very rare incidence of two 
histologically different malignancies with the same 
BRAF mutation in a patient that clearly showed the 
effectiveness of such targeted therapy involving 
different organ systems.
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